B
Barry Jones
Researcher at Eli Lilly and Company
Publications - 49
Citations - 3671
Barry Jones is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Risperidone. The author has an hindex of 28, co-authored 49 publications receiving 3600 citations. Previous affiliations of Barry Jones include University of Ottawa & McMaster University.
Papers
More filters
Journal ArticleDOI
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Guy Chouinard,Barry Jones,Gary Remington,D. Bloom,Donald Addington,G.W. MacEwan,Alain Labelle,Linda Beauclair,Wendy Arnott +8 more
TL;DR: It is suggested that risperidone, at the optimal therapeutic dose of 6 mg/day, produced significant improvement in both positive and negative symptoms without an increase in drug-induced parkinsonian symptoms and with a significant beneficial effect on tardive dyskinesia.
Journal ArticleDOI
Neuropsychological Change in Early Phase Schizophrenia During 12 Months of Treatment With Olanzapine, Risperidone, or Haloperidol
Scot E. Purdon,Barry Jones,Barry Jones,E. Stip,Alan Labelle,Don Addington,S.R. David,Alan Breier,Gary D. Tollefson +8 more
TL;DR: Olanzapine has some superior cognitive benefits relative to haloperidol and risperidone, and a larger sample replication study is necessary to confirm and generalize the observations of this study.
Journal ArticleDOI
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
Guy Chouinard,Barry Jones +1 more
TL;DR: An implication of neuroleptic-induced mesolimbic supersensitivity is that the tenaency toward psychotic relapse in such patients is determined by more than just the normal course of the illness.
Journal ArticleDOI
Neuroleptic-Induced Supersensitivity Psychosis
TL;DR: The anticholinergic effects of chlorpromazine, amitriptyline, scopolamine (Sominex) (0), and tropicamide were probably additive and although her disorientation cleared rapidly, Ms. A maintained that her hallucinations persisted during her 2-week hospitalization.
Journal ArticleDOI
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
Karena Meehan,Huei Wang,S.R. David,Jennifer R. Nisivoccia,Barry Jones,Charles M. Beasley,Peter D. Feldman,Jacobo Mintzer,Louise M. Beckett,Alan Breier +9 more
TL;DR: Intramuscular injection of olanzapine may provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation and no significant differences among treatment groups were seen in vital signs, including orthostasis.